82129-45-1

Usage

Uses

Used in Pharmaceutical Industry:
2-ethoxy-6-fluorobenzaldehyde is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of various medicinal compounds.
Used in Agrochemical Industry:
2-ethoxy-6-fluorobenzaldehyde is used as an intermediate in the synthesis of agrochemicals, playing a role in the creation of substances for agricultural applications.
Used in Fragrance Industry:
2-ethoxy-6-fluorobenzaldehyde is used as a building block for the production of various fragrances due to its pleasant odor, enhancing the scent profiles of different products.
Used in Flavor Industry:
2-ethoxy-6-fluorobenzaldehyde is used as a flavoring agent in food products, contributing to the taste and aroma of various consumables.
Used in Organic Synthesis:
2-ethoxy-6-fluorobenzaldehyde is employed as a reagent in organic synthesis reactions, facilitating the creation of a range of organic compounds.

Upstream product

• 458-03-7 1-ethoxy-3-fluorobenzene 
• 68-12-2 N,N-dimethyl-formamide 
• 38226-10-7 2-fluoro-6-hydroxybenzaldehyde 
• 75-03-6 ethyl iodide 
• 372-20-3 3-fluorophenol 

Downstream Products

• 149489-16-7 2-(2-ethoxy-6-fluorophenyl)ethylamine 
• 172505-89-4 1-(5-Bromo-pyridin-2-yl)-3-[2-(2-ethoxy-6-fluoro-phenyl)-ethyl]-thiourea 
• 82129-46-2 2-(2-ethoxy-6-fluorophenyl)-2-trimethylsiloxyethanenitrile 

Relevant academic research and scientific papers

ANTITUMOR EFFECT POTENTIATOR COMPRISING PYRROLOPYRIMIDINE COMPOUND

Disclosed is an antitumor effect potentiator for one or more other compounds having an antitumor effect, the antitumor effect potentiator comprising a novel pyrrolopyrimidine compound.

NOVEL PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, ESPECIALLY AGENT FOR PREVENTION AND/OR TREATMENT OF TUMORS ETC BASED ON NAE INHIBITORY EFFECT

An object to be solved by the present invention is to provide a novel pyrrolopyrimidine compound or a salt thereof having an NAE inhibitory action and a cell growth inhibitory effect. The present invention provides a compound or a salt thereof represented by Formula (A), as well as an NAE inhibitor, a pharmaceutical composition, and an antitumor agent comprising the compound or a salt thereof as an active ingredient.

Method for inhibition of HIV related viruses

Treatment of AIDS, inhibition of the replication of HIV and related viruses thereof, and formulations using thiourea derivative compounds or salts thereof is disclosed. Also disclosed are novel thiourea derivative compounds.

Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs

Phenylethylthiazolylthiourea (PETT) derivatives have been identified as a new series of nonnucleoside inhibitors of HIV-1 RT. Structure-activity relationship studies of this class of compounds resulted in the identification of N-[2-(2-pyridyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea hydrochloride (trovirdine; LY300046.HCl) as a highly potent anti-HIV-1 agent. Trovirdine is currently in phase one clinical trials for potential use in the treatment of AIDS. Extension of these structure-activity relationship studies to identify additional compounds in this series with improved properties is ongoing. A part of this work is described here. Replacement of the two aromatic moleties of the PETT compounds by various substituted or unsubstituted heteroaromatic rings was investigated. In addition, the effects of multiple substitution in the phenyl ring were also studied. The antiviral activities were determined on wild-type and constructed mutants of HIV-1 RT and on wild-type HIV-1 and mutant viruses derived thereof, Ile100 and Cys181, in cell culture assays. Some selected compounds were determined on double- mutant viruses, HIV-1 (Ile100/Asn103) and HIV-1 (Ile100/Cys181). A number of highly potent analogs were synthesized. These compounds displayed IC50's against wild-type RT between 0.6 and 5 nM. In cell culture, these agents inhibited wild-type HIV-1 with ED50's between I and 5 nM in MT-4 cells. In addition, these derivatives inhibited mutant HIV-1 RT (Ile 100) with IC50's between 20 and 50 nM and mutant HIV-1 RT (Cys 181) with IC50's between 4 and 10 nM, and in cell culture they inhibited mutant HIV-1 (Ile100) with ED50's between 9 and 100 nM and mutant HIV-1 (Cys181) with ED50's between 3 and 20 nM.

Hypoglycemic 5-substituted oxazolidine-2,4-diones

Hypoglycemic 5-phenyl and 5-naphthyl oxazolidine-2,4-diones and the pharmaceutically-acceptable salts thereof; certain 3-acylated derivatives thereof; a method of treating hyperglycemic animals therewith; and intermediates useful in the preparation of said compounds.